

Izervay[™] (avacincaptad pegol) – Updated dosing

- On February 12, 2025, <u>Astellas announced</u> the FDA approval of a label update for <u>Izervay</u> (avacincaptad pegol), removing the limitation that it could only be used for up to 12 months.
- Izervay is approved for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- The approved label update was based on positive results from the GATHER2 study, which evaluated the efficacy and safety of Izervay through year 2.
 - In the GATHER2 study, Izervay continued to reduce the rate of GA lesion growth in patients with GA secondary to AMD through 2 years vs. sham. The treatment benefit with Izervay vs. sham was observed as early as 6 months, continued to increase over time through 2 years, and more than doubled over 2 years compared to year 1.
- The recommended dose of Izervay is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.